Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?

Joel R. Rosh, Thomas Gross, Petar Mamula, Anne Griffiths, Jeffrey Hyams

Research output: Contribution to journalReview article

210 Citations (Scopus)

Abstract

Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL) - a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

Original languageEnglish (US)
Pages (from-to)1024-1030
Number of pages7
JournalInflammatory bowel diseases
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

T-Cell Lymphoma
Crohn Disease
Young Adult
Biological Therapy
Inflammatory Bowel Diseases
Non-Hodgkin's Lymphoma
Lymphoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Cite this

Rosh, Joel R. ; Gross, Thomas ; Mamula, Petar ; Griffiths, Anne ; Hyams, Jeffrey. / Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease : A cautionary tale?. In: Inflammatory bowel diseases. 2007 ; Vol. 13, No. 8. pp. 1024-1030.
@article{9b1ea9c0ae7a4a349a2b790331e99795,
title = "Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?",
abstract = "Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL) - a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.",
author = "Rosh, {Joel R.} and Thomas Gross and Petar Mamula and Anne Griffiths and Jeffrey Hyams",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/ibd.20169",
language = "English (US)",
volume = "13",
pages = "1024--1030",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease : A cautionary tale? / Rosh, Joel R.; Gross, Thomas; Mamula, Petar; Griffiths, Anne; Hyams, Jeffrey.

In: Inflammatory bowel diseases, Vol. 13, No. 8, 01.08.2007, p. 1024-1030.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease

T2 - A cautionary tale?

AU - Rosh, Joel R.

AU - Gross, Thomas

AU - Mamula, Petar

AU - Griffiths, Anne

AU - Hyams, Jeffrey

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL) - a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

AB - Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL) - a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

UR - http://www.scopus.com/inward/record.url?scp=34347369156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347369156&partnerID=8YFLogxK

U2 - 10.1002/ibd.20169

DO - 10.1002/ibd.20169

M3 - Review article

C2 - 17480018

AN - SCOPUS:34347369156

VL - 13

SP - 1024

EP - 1030

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 8

ER -